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Abstract
Background: The prolyl-hydroxylase domain family of enzymes (PHD1-3) plays an important role in the cellular response to
hypoxia by negatively regulating HIF-a proteins. Disruption of this process can lead to up-regulation of factors that promote
tumorigenesis. We observed decreased basal expression of PHD3 in prostate cancer tissue and tumor cell lines representing
diverse tissues of origin. Furthermore, some cancer lines displayed a failure of PHD3 mRNA induction when introduced to a
hypoxic environment. This study explores the mechanism by which malignancies neither basally express PHD3 nor induce
PHD3 under hypoxic conditions.
Methodology/Principal Findings: Using bisulfite sequencing and methylated DNA enrichment procedures, we identified
human PHD3 promoter hypermethylation in prostate, breast, melanoma and renal carcinoma cell lines. In contrast, non-
transformed human prostate and breast epithelial cell lines contained PHD3 CpG islands that were unmethylated and
responded normally to hypoxia by upregulating PHD3 mRNA. Only treatment of cells lines containing PHD3 promoter
hypermethylation with the demethylating drug 5-aza-29-deoxycytidine significantly increased the expression of PHD3.
Conclusions/Significance: We conclude that expression of PHD3 is silenced by aberrant CpG methylation of the PHD3
promoter in a subset of human carcinoma cell lines of diverse origin and that this aberrant cytosine methylation status is the
mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA. We further show that a loss of PHD3 expression
does not correlate with an increase in HIF-1a protein levels or an increase in the transcriptional activity of HIF, suggesting
that loss of PHD3 may convey a selective advantage in some cancers by affecting pathway(s) other than HIF.
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Introduction
The cellular response to reduced oxygen availability (hypoxia) is
controlled by a class of proteins called hypoxia-inducible factors
(HIF-a). There are 3 known isoforms of HIF-1a: HIF-1a, HIF-2a
and HIF-3a. HIF-1a and HIF-2a are transcription factors. HIF-
3a appears to lack transcriptional activity and may play a role in
negative regulation of the HIF pathway [1]. Thus, from here on,
when referring to HIF-a, we are referring to only HIF1 and HIF2.
Transcriptionally active HIF1 and 2 are heterodimers composed
of the HIF-a subunit and aryl hydrocarbon nuclear translocator
receptor (ARNT/HIF-b)HIF-1a activates the transcription of
EPO, VEGF, heme oxygenase-1 and several other critical
intracellular responses to hypoxia including enzymes of the
glycolytic pathway [2,3]. While less is known about HIF-2a
transcriptional targets, HIF-2a appears to play a lesser role in the
glycolytic response with more emphasis on EPO and VEGF
transcription [4].
HIF-a mRNA levels are generally stable in cells. It is not until
after translation that HIF-a is tightly controlled. During periods of
normal physiological oxygen concentration, HIF-a subunits are
kept at low levels by constant proteolytic degradation. First, a
hydroxylation reaction is catalyzed by a family of prolyl
hydroxylase domain-containing proteins (PHD/EGLN/HPH)
which utilize iron, oxygen and 2-oxoglutarate as co-factors to
enzymatically catalyze hydroxylation on the oxygen-dependent
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ated proline residues on HIF-a are recognized by Von Hippel-
Lindau (VHL) protein, an E3 ubiquitin ligase that ubiquitinates
the HIF-a subunit, targeting it to the proteosome [6]. Under
hypoxic conditions, HIF prolyl hydroxylase activity is decreased
and HIF-1a protein accumulates. HIF-a subunits translocate to
the nucleus and dimerize with the constitutively expressed ARNT
subunit [7,8]. This heterodimer acts to turn on transcription of
genes involved in oxygen homeostasis and glucose metabolism [2].
Three main isoforms of HIF prolyl-hydroxylase domain
containing proteins, PHD1-3, have been identified [9]. These
isoforms have been reported to have different specificities for HIF-
1a and HIF-2a [10], and also differ in their subcellular
localization. It has been shown that PHD1 is exclusively present
in cytoplasm, PHD2 is mainly located in the nucleus and PHD3 is
evenly distributed in both cytoplasm and nucleus [11]. PHD2 and
PHD3, however, are considered to be the major isoforms that
contribute to HIF-1 and -2a degradation in cells [12,13]. In
normoxia, PHD2 is the primary enzyme that hydroxylates HIF-1a
[14], whereas PHD3 has been reported to play an important role
in HIF-2a hydroxylation and also in retaining cellular hydroxyl-
ation capacity in a hypoxic environment [10,15].
In normal cells, PHD3 mRNA and protein are expressed at low
levels during normoxia, but are significantly induced upon
exposure to hypoxia. In contrast, PHD3 expression in a significant
number of cancer cell types has been shown to be low or absent
not only during normoxia, but also under hypoxic conditions
[10,16]. To date, no mechanism has been discovered to explain
this defect in hypoxic inducibility. Interestingly, Hatzimichael et
al. have recently demonstrated that the promoter of PHD3 is
methylated in certain primary B-cell dyscrasias [17]. We had
observed a decrease in PHD3 mRNA expression in human breast
and prostate carcinoma cell lines, with an absence of PHD3
upregulation in response to hypoxia. Therefore, we were
interested to determine whether PHD3 promoter methylation
was responsible for this aberrant expression pattern. In this study,
we show that the promoter region of PHD3 is methylated in
representative human prostate carcinoma, melanoma, renal
carcinoma and breast cancer cell lines. Furthermore, we show
that neither HIF-1a protein levels nor hypoxic response through
an HRE-luciferase reporter vector are compromised in PHD3
methylated compared to non-methylated cell lines. These results
indicate that PHD3 promoter methylation is utilized by malig-
nancies derived from diverse human cell types. Furthermore, these
data suggest that loss of PHD3 expression may not affect the
transcriptional response through the HIF pathway, leaving open
the possibility that PHD3 silencing in tumors is selected through
the loss of specific interactions with other cellular pathways.
Methods
Cell culture
Normal human prostate epithelial cells (NPrEC) were pur-
chased from Clonetics, Lonza Inc. (Walkersville, MD) and were
grown on the recommended PrEGM media supplied by Clonetics,
Lonza Inc. The hTERT-HME1 cells were cultured in mammary
epithelial basal medium MEGM (Lonza Inc.) at 37uC and 5%
CO2 according to the manufacturer’s instructions (Lonza Inc.).
The DU 145, 22RV.1, PC-3, MDA-MB-435 (MB-435), and
MCF7 cell lines were obtained from ATCC (Manassas, VA).
MCF7, DU145 and MDA-MB-435 cells were cultured in Eagle’s
Minimum Essential Medium (MEM) supplemented with 10% fetal
bovine serum (FBS). PC-3 cells were cultured in F12 medium
supplemented with 10% FBS, 2 mM L-glutamine, 1 mM Na
Pyruvate, and supplemented with 100 U/ml pen/strep. All cell
lines were routinely maintained at 37uC in a humidified
atmosphere with 5% CO2. Fresh media was replaced every three
days while routine subculture was performed by washing with 1X
PBS and detaching cells with TrypLE Express.
Semi-quantitative RT-PCR
Total RNA was extracted from individual cell lines using RNeasy
Mini Kit (Qiagen, Valencia, CA) and quantified using a NanoDrop
1000. To assess PHD3 and GAPDH expression, 500 ng of total RNA
was used for reverse transcription using a OneStep RT-PCR Kit
(Qiagen). The PHD3 forward primer is 59-GGGCAAATAC-
TACGTCAAGGAG-39 and the reverse primer is 59-AGTCTT-
CAGTGAGGGCAGATTC-39. GAPDH expression was assessed
using GAPDH-specific primers. PCR conditions for PHD3 and
GAPDHwerethesameexceptthat28cyclesofPCRwereperformed
for PHD3 analysis and 23 cycles were performed for GAPDH. The
parameters used were: 95uC for 5 minutes followed by the stated
number of cycles of 94uC for 1 minute; 56uCf o r1m i n u t e ,a n d7 2 uC
for1minute,endingwithafinalextensionat72uCf o r7m i n u t e s .T h e
amplified products were electrophoresed on a 1% agarose gel and
stained with ethidium bromide to visualize the bands.
Quantitative real time RT-PCR
Total RNA was isolated from cells using Trizol, followed by
DNAse treatment and NaOAc precipitation. The reverse transcrip-
tion reaction was carried out with High-Capacity cDNA Archive
Kit (Applied Biosystems, Foster City, CA). PHD3 TaqMan primer-
probe was utilized from Applied Biosystems (Hs00222966_m1).
Thequantitative real-timePCRwassetupasfollows:10 ngofRNA
was used as template for each real-time PCR reaction (10 mg
reaction volume); primer pairs at 0.3 mM for GAPDH with Syber
Green Master Mix (Applied Biosystems). For PHD3, TaqMan
universal master mix was used. The DNA polymerase was activated
by heat at 95uC for 10 min followed by 40 cycles, denaturing at
95uC for 15 s, annealing and elongating at 60uC for 1 min. Data
were collected with ABI PRISM 7000 sequence detection system.
Data were analyzed using the DDCt method.
Western Blot analysis
Cells were immediately washed with ice cold phosphate-
buffered saline (pH 7.4). Cells were lysed on the plate in 200 ml
RIPA cell-lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1%
SDS, 0.5% Na Deoxycholate, 1% TX-100) plus 1 mM NaF,
10 mM NaVO4, 10 mM PMSF, and 1/100 protease inhibitor
cocktail (Sigma), immediately boiled for 2 minutes and then
sonicated. SDS-polyacrylamide gels (7%, PHD3; 15% HIF1,
HIF2) were used for protein electrophoresis. Proteins were
electrotransferred onto nitrocellulose membranes and treated with
anti HIF-1a (Abcam, Cambridge, MA) 1:500 overnight at 4uC.
Anti PHD3, NB100-139 and anti HIF-2a antibodies (Novus
Biologicals, Littleton, CO) were used at 1:500 and 1:200
respectively overnight at 4uC. Equal protein loading was
confirmed on all immunoblots using human actin antibody
(Sigma, St. Louis, MO) at a dilution 1:2000. Goat anti-rabbit
IgG (BD Transduction Laboratories, San Diego, CA) was used as
a secondary antibody against all primary antibodies. Bands were
visualized by chemiluminescence with ECL plus reagent (Pierce,
Rockford, IL) on a Typhoon FLA 7000.
Sodium bisulfite sequencing
Genomic DNA was extracted with the use of the DNeasy Tissue
Kit (Qiagen, Valencia, CA), and sodium bisulfite conversion was
Mechanism of PHD3 Silencing
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Research Corporation, Orange, CA). A pair of primers was
designed to amplify the PHD3 promoter of both bisulfite modified
methylated and unmethylated DNA but not unmodified DNA.
Nested PCR amplification on converted DNA used the following
primers: outside forward: 59-GTGTGGGATTTAGGTTTT-
TAAG-39 (SB1); outside reverse:59-CCAAATCCAACCTCA-
TAATATATC-39 (SB2); and nested inner primers (SB3) and
(SB4) whose sequences and locations are described in detail below.
The resulting PCR products were gel-extracted with the use of
the Qiagen Gel Extraction Kit, or gel digestion with b-agarase
followed by EtOH precipitation, and cloned with the TOPO TA
Cloning Kit (Invitrogen). Plasmid DNA was extracted with the use
of the QiaPrep Spin Plasmid Miniprep Kit (Qiagen). Sequencing
was performed by the sequencing core facility maintained by the
University of Iowa and results were tabulated for methylation
status of each of the 58 CpGs contained in the amplicons from
each cell line.
5-Aza-dC treatment
Cells were counted, and seeded (day 0) at approximately
750,000 cells/100 mm dish. Fresh 5-Aza-dC (5 mM) was added to
the dish on days 1, 3, and 5 while a control flask was left untreated.
On day 5, 5-Aza-dC treated cells were split into two 60 mm dishes
in media supplemented with 5 mM 5-Aza-dC. On day 6, one of
each of the 60 mm dishes was placed in a hypoxia chamber and
placed under 1%O2, 94%N2 and 5% CO2 at 37uC. On day 7, all
cells were harvested with 500 ml Trizol for RNA extraction.
Chromatin Accessibility
Chromatin accessibility experiments were conducted as previ-
ously described by Rose et al. [18]. The primers CA1 and CA2
were located within the region of the PHD3 gene queried for DNA
methylation (primer sequences and locations described in detail
below). After nuclei extraction and a 5 minute DNase I digestion
the DNA was extracted and real-time PCR was conducted on an
ABI 7000 Sequence Detection System. The accessibility index for
each amplicon was then determined by the following formula
(accessibility index = 2
((Ct Dnase treated) 2 (Ct Uncut))). GAPDH
chromatin accessibility was also determined as a positive control
for a constitutively expressed gene to control for equivalent DNase
digestion between the cell lines examined.
HRE-Luciferase assay
Cell lines ,85% confluent in 60 mm dishes were transfected
with an HRE-luciferase reporter vector [19] (2.5 mg) and Renilla
luciferase (1.5 mg) according to Lipofectamine 2000 transfection
reagent protocol. Transfection media was removed after 6 hours
and replaced with fresh medium. Cells we then placed under 94%
N2,5 %C O 2,1 %O 2 gas mixture in a hypoxia chamber, or
normoxia for 24 hours and then lysed according to the Dual
luciferase reporter assay system (Promega, Madison, WI) protocol.
Luminescence was measured 3 times per sample using a Tecan
SpectraFluor Plus luminometer.
Adenoviral Transduction
The adenoviral PHD3 construct was a generous gift from Dr.
Robert Freeman from Rochester University (unpublished).
Briefly, the human PHD3 coding sequence was engineered
into the pDC315 vector and contains an N-terminal FLAG tag.
PC3 cells were grown to ,85% confluency and then
transduced with 20, 40 or 60 MOI of Ad-PHD3. Approxi-
mately 36 hours following transduction, cells were lysed with
RIPA buffer and western blotted according to the procedures
outlined above.
Clinical Samples
Clinical prostate tumor samples were received as frozen blocks
in OCT. Sections were cut and ground with mortal and pestle.
DNA and RNA were extracted in with Qiagen DNeasy Tissue kit
and Trizol respectively.
Methylated DNA Enrichment
Genomic DNA was harvested from cells and tissue using a
Qiagen DNeasy Tissue kit. 2 mg of DNA in 120 ml of 10 mM Tris
pH 8.0 was sonicated into fragments of approximately 150 bp
using a Covaris S2. Fragmentation was done according to the
Covaris protocol. 1 mg (60 ml) of sheared input gDNA was used
according to the protocol supplied by the MethylMiner kit
(Invitrogen). Binding reactions between beads containing methyl-
CpG binding domains and sheared genomic DNA were
performed at 4uC overnight. Bound DNA was eluted using
progressively increasing NaCl concentrations. Eluates were
precipitated using NaOAc and EtOH precipitation and resus-
pended in 60 ml 10 mM Tris pH 8.0. Real time PCR was
performed using 1 ml resuspended DNA, SYBR Green master mix
and 100 nM Fwd Primer: 59-GAGCTCCACGACCCGTTTC-39
and Rev Primer: -59-GCAGTGGTGGCTTCCCAT-39 in a 10 ml
reaction volume. The kit was validated using samples from human
tumor cell lines with know PHD3 CpG island methylation status as
determined by bisulfite sequencing (Figure S1).
Statistical Analysis
Significant differences between groups of data were determined
using a t-test for all bar graphs or ANOVA for box plot powered
by SigmaPlot 11.0 software. n=3 was used for each data set unless
otherwise noted.
Results
PHD3 mRNA is aberrantly silenced in human melanoma,
prostate and breast carcinoma cell lines
A panel of human carcinoma cell lines was screened for PHD3
mRNA expression. This panel consisted of three prostate cancer
cell lines (DU 145, 22RV.1 and PC-3), two breast cancer cell lines
(MCF7, HS578T), one melanoma (MDA-MB-435), a non-
transformed prostate epithelial cell line (NPrEC) and a non-
transformed, immortalized breast cell line (hTERT-HME1). We
found that PHD3 mRNA was expressed at different levels varying
from abundant to almost undetectable levels as determined by
conventional RT-PCR (Figure 1a). The prostate cancer cell lines
showed decreased PHD3 mRNA expression compared to the
normal prostate epithelial cells. A comparison of three prostate
cancer cell lines showed that PHD3 is expressed in DU 145 and 22
RV.1, whereas in PC-3, PHD3 mRNA is nearly undetectable. The
melanoma cell line, MDA-MB-435 was also found to have very
low PHD3 mRNA expression. Among the mammary cell lines,
HS578T had much lower PHD3 mRNA than the HME1
mammary epithelial cells and MCF7 cells expressed far more
PHD3 mRNA than its normal HME1 mammary epithelial cell
counterpart. To confirm and extend the results shown in
Figure 1a, quantitative real time RT-PCR analysis of PHD3
mRNA expression were conducted and the results are shown in
Figure 1b. Similarities in expression were found with both the
methods used, and PHD3 mRNA expression was nearly
undetectable in PC-3, MDA-MB-435 and HS578T cell lines.
Mechanism of PHD3 Silencing
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inhibitor 5-Aza-dC
The near absence of PHD3 mRNA expression in a subset of cell
lines suggested an epigenetic mechanism might be responsible for
their silencing. Unlike genetic mutations that accumulate in
cancer, epigenetic modifications are reversible [20]. We hypoth-
esized that if DNA methylation of the PHD3 gene was responsible
for its reduced expression, a DNA methyltransferase inhibitor such
as 5-Aza-29-deoxycytidine (5-Aza-dC) should induce its expression.
This is in line with 5-Aza-dC’s purported ability to re-activate
genes previously silenced by DNA methylation in cancer cells [21].
We chose 2 cell lines displaying the most marked decrease in
PHD3 expression, MB-435 and PC-3, and 2 cell lines displaying
moderate to high basal PHD3 expression, MCF7 and DU 145 for
treatment with 5-Aza-dC. When MB-435 and PC-3 cells were
treated with 5-Aza-dC, there were significant increases in the
PHD3 mRNA expression compared to their respective untreated
controls (Figure 2). Furthermore, MB-435 cells became respon-
sive to PHD3 mRNA upregulation by hypoxia to a significant
degree following hypoxic exposure. Cells that already expressed
PHD3 at moderate levels did not respond to 5-Aza-dC by
significantly upregulating PHD3. Although this finding suggests
that CpG methylation is involved in silencing, further direct
queries of epigenetic alterations at this locus were necessary to
more deeply address this question.
The PHD3 CpG island is aberrantly CpG methylated and
displays decreased chromatin accessibility in human
carcinoma cells
To determine whether PHD3 gene methylation is present at the
CpG island in cell lines that have reduced PHD3 mRNA
expression and respond to 5-Aza-dC by upregulating PHD3
mRNA, we utilized sodium bisulfite sequencing to identify
methylated CpG sites. Figure 3A, illustrates the CpG island in
the 59-end of the PHD3 gene. The 58 CpG sites in the region
analyzed are represented by vertical lines. A putative hypoxia
response element (HRE) in the promoter region of the gene is also
indicated. We found that these CpGs were highly methylated in
Figure 1. Differential expression of PHD3 mRNA in normal and tumor cell lines of prostate, breast and melanoma origin. Total RNA
was extracted from the indicated cell lines. A) Expression of mRNA was determined by semiquantitative RT-PCR using specific primers designed to
amplify PHD3 and GAPDH. The RT-PCR products were electrophoresed using 1% agarose gel, with ethidium bromide to show bands of expected
sizes. GAPDH was used as the loading control. B) Quantitative real-time reverse transcription-PCR analysis of PHD3 was performed with normalization
to 18S rRNA gene expression and relative quantities were determined by the DDCt method. The data shown are the PHD3 gene expression of
individual cancer cell lines relative to those of their corresponding normal counterparts (PrEC for prostate and HMEC-hTERT for mammary).
doi:10.1371/journal.pone.0014617.g001
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(Figure 3B). These represent examples of human melanoma,
prostate, and mammary carcinoma cells respectively. We also
noted that many cell lines appeared to be heterogeneous with
respect to PHD3 promoter methylation status. Within certain cell
lines, some clones display high levels of methylation, whereas other
have very few to no methylated CpGs. This small population of
unmethylated or hemimethylated cells within a cell line may
explain our ability to detect very low levels of PHD3 mRNA in cell
lines displaying largely methylated PHD3 CpG islands. Further-
more, areas of CpG methylation in some methylation positive cell
lines overlap with a putative HRE in the PHD3 promoter region,
which could hinder the ability of PHD3 to be induced upon
hypoxic stimuli. In contrast to the positive methylation status in
PHD3 negative cells, the CpGs in the PHD3 CpG island were
largely unmethylated in the PHD3 positive cells, NPrEC, DU 145,
22RV.1, HME1, and MCF7.
DNA methylation is typically associated with other alterations to
chromatin structure that participate in cell-type specific gene
expression patterns. Aberrant cytosine methylation in the 59-
regulatory regions of genes is typically associated with deacetylated
histones, and thus a state of DNA that is generally inaccessible to
transcription factors and other enzymes that act on DNA, such as
polymerase II. This is a mechanism of gene silencing often
exploited by cancer cells [22]. In a chromatin accessibility assay,
we found the promoter region of PHD3 in PC-3 cells was resistant
to cutting by DNase I when compared to the MCF7 PHD3
promoter, whereas there was little change in GAPDH promoter
accessibility between the two cell lines (Figure S2). This evidence
further supports the hypothesis that PHD3 promoter methylation
and heterochromatin formation are part of the mechanism for
reduced expression of PHD3 in these human breast and prostate
cancer cell lines.
PHD3 expression is not induced upon exposure to
hypoxia in cell lines containing PHD3 promoter
methylation
Unlike PHD1, both PHD2 and PHD3 genes contain hypoxia
response elements, and can be induced by hypoxia by the HIF-1
and HIF-2 transcription factor complex. In the case of PHD3,
mRNA and protein expression can be relatively low during
normoxic conditions, with marked increases upon hypoxic insult
[10]. Therefore, we tested PC-3, DU 145, MB-435 and MCF7 cell
lines for their ability to upregulate PHD3 following 24 hours of
hypoxia (1% O2)( Figure 4A). We found cell lines that contained
PHD3 promoter methylation (PC-3, MB-435) failed to appreciably
upregulate PHD3 mRNA under these conditions. However, we
did note a very small upregulation of PHD3 mRNA in PC-3 cells.
This can likely be attributed to the heterogeneity of PHD3
promoter methylation between specific clones in this cell line (see
figure 3B). In contrast, PHD3 mRNA was much more prone to
upregulation in the unmethylated cell line MCF7. Upregulation of
PHD3 in DU 145 cells varied by experiment, and averaged as a
non-significant trend toward hypoxic upregulation.
Our discovery of PHD3 promoter methylation in melanoma,
breast and prostate cancer cell lines prompted us to ask whether
cell lines from other malignant tissues contained methylation at the
PHD3 locus. Therefore, we further performed real-time PCR and
bisulfite sequencing on a panel of 3 human renal cell carcinoma
cell lines (A-498, ACHN and 769-P), and on cDNA prepared from
normal kidney tissue (Figure 4B). We found that ACHN and
769-P cells express nearly undetectable levels of PHD3 mRNA,
whereas A-498 expresses levels comparable to normal tissue. Of
these cell lines, the PHD3 positive A-498 displayed an unmethy-
lated PHD3 promoter whereas 769-P cells displayed an aberrantly
methylated PHD3 promoter. Interestingly though, we did not
detect any CpG methylation at the promoter of PHD3 negative
Figure 2. Treatment with 5-Aza-dC triggers re-expression of PHD3. Cell lines representative of PHD3 expressers and PHD3 non-expressers
were either not treated (C), treated with hypoxia (H), treated with 5-Aza-dC (Aza), or treated with 5-Aza-dC and then subjected to 1% oxygen (Aza +
H) according to the protocol described in Materials and Methods. Real time quantitative PCR was performed to determine the mRNA expression of
PHD3. The data were normalized to GAPDH and expressed relative to PHD3 mRNA in the corresponding untreated controls. Error bars = SEM. n=3.
doi:10.1371/journal.pone.0014617.g002
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this cell line.
PHD3 promoter methylation status does not correlate
with hypoxia induced HIF-1a protein accumulation or HIF
transcriptional activity
The presence of PHD3 promoter methylation in such a broad
range of epithelial malignancies suggests that it may be a selective
advantage for tumor survival. One hypothesis is that PHD3 silencing
by promoter methylation may allow for an increased HIF
transcriptional response during hypoxic conditions. In order to
determine whether PHD3 promoter methylation specifically affects
the hypoxia response pathway, we performed western blots on cell
lysatesfromMCF7,PC-3,MB-435andDU145celllinestocompare
the HIF protein levels and the HIF transcriptional response to
hypoxia (Figure 5a). Following 24 hours of hypoxia, HIF-1a
protein was upregulated in all the cell lines regardless of PHD3
expression status. We also observed that DU 145 cells appear not to
express detectable levels of PHD3 protein. We are unsure whether
this is due to limits of detection by our PHD3 antibody, or if DU 145
cells downregulate PHD3 expression by a posttranslational mecha-
nism.Our antibody appears to be specific to PHD3 as transduction of
an adenoviral-PHD3 expression vector into PC3 cells produces a
band at an identical molecular weight as the band seen in MCF7 cells
(Figure S3). Interestingly though, MCF7 cells, which do express
basal levels of PHD3 mRNA and protein, displayed the largest
induction of HIF-1a protein. Thus, HIF-1a protein levels, in general,
did not show any correlation with presence or absence of PHD3. We
also found HIF-2a to be expressed under normoxic conditions in
MCF7. Moreover, MB-435 cells, which express the lowest levels of
PHD3 mRNA out of all the cell lines tested appear not to express
HIF-2a at an appreciable level. Thus, loss of PHD3 does not appear
to be significantly correlated with an accumulation of HIF-1a or HIF-
2a levels in these cell lines.
To further investigate the effect of PHD3 promoter methylation
on the transcriptional response of the hypoxia response pathway,
Figure 3. DNA methylation analysis of the PHD3 59-CpG island in human melanoma, prostate and breast carcinoma cell lines. A)
Schematic representation of the CpG distribution in the 59-regulatory region of the PHD3 gene from UCSC Genome Browser coordinates
bp34420511-bp34419838. The CpG sites are represented by vertical tick marks, and the beginning of exon 1 is depicted as a bent arrow. The
locations of PCR primers used to assess genomic methylation (SB3 and SB4) and chromatin accessibility (CA1 and CA2), respectively. B) Bisulfite
sequencing was performed on DNA isolated from two non-tumorigenic epithelial cell lines (NPrEC and hTERT-HME1) and six tumor cell lines (DU 145,
22RV.1, PC-3, MB-435, HS578T, and MCF7). Each grid contains at least 5 rows representing the 5 individually cloned and sequenced bisulfite PCR
products from the indicated cell lines. Each row contains 58 boxes representing the 58 CpGs in an individual cloned molecule. Open and filled boxes
are unmethylated and methylated CpG sites, respectively.
doi:10.1371/journal.pone.0014617.g003
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lines with an HRE-luciferase reporter construct [19]. Following
24 hours of hypoxia, luciferase activity was measured and plotted
relative to luciferase activity in normoxic cells (Figure 5B). There
was no correlation between PHD3 promoter methylation status
and hypoxic induction of luciferase. The results of this experiment
resembled the pattern of HIF-1a protein accumulation seen in
figure 5A. MCF7 cells showed the largest induction luciferase
activity, whereas the other cell lines, which do not express
detectable levels of PHD3 protein, were comparable to one
another. Although not absolute, these data are highly suggestive
that HIF protein stabilization and transcriptional activity is largely
independent of PHD3 expression.
PHD3 promoter methylation is absent in primary human
prostate adenocarcinomas
Recent data published by Hatzimichael et al. suggested that
acquisition of PHD3 promoter methylation may be a relatively
common event in certain plasma cell neoplasias [17]. There-
fore, we asked whether primary human prostate neoplasias
contained methylation at the PHD3 CpG island. We extracted
D N Aa n dR N Af r o mf r o z e ns e c t i o n so f1 0p r o s t a t ec a n c e r
specimens containing a minimum of 70% malignant tissue with
a Gleason score ranging from 7–9 as well as 3 benign prostate
specimens. Real-time PCR of extracted RNA showed that all
10 tumors contained decreased PHD3 mRNA expression
compared to 3 benign tissue specimens (Figure 6A and B).
Figure 4. The methylated PHD3 gene in melanoma, prostate, breast and renal carcinoma cell lines is refractory to induction by
hypoxia. A) Melanoma, prostate and breast carcinoma cell lines were treated with hypoxia (1% O2) or normoxia (21% O2) for 24 hours. Total RNA
was extracted and converted to cDNA by reverse transcription. Quantitative real-time reverse transcription-PCR analysis of PHD3 was performed with
normalization to GAPDH gene expression. Relative quantitation was determined by the DDCt method. ND = not detectable. Error bars = SEM. n=3.
B) Renal clear cell carcinoma cell lines were either untreated or treated with hypoxia as in A). The right panel depicts relative PHD3 mRNA levels
compared to mRNA extracted from normal renal tissue. The left panel depicts the methylation status at each of 58 CpG dinucleotides present in the
PHD3 CpG island of the representative renal carcinoma cell lines. Error bars = SEM. n=3.
doi:10.1371/journal.pone.0014617.g004
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methylated CpGs at the PHD3 CpG island in tumor sample 1
(Figure S4), which also contained the lowest PHD3 mRNA
levels. However, further bisulfite sequencing of 8 clones from
tumor sample 1 and tumor sample 4 did not detect any
methylated CpGs (data not shown). This could be due to better
sensitivity to population average methylation states as com-
pared to the single molecule at a time approach of bisulfite
sequencing.
Figure 5. The HIF-1 response is not impaired in prostate and breast carcinoma cell lines that lack PHD3.A ) Melanoma, breast and
prostate cancer cell lines with methylated PHD3 promoters (MB-435, PC-3) and non-methylated promoters (MCF7, DU 145) were subjected to hypoxia
(1% O2) or normoxia for 24 hours. Thirty micrograms of whole cell lysate was western blotted for the presence of HIF-1a, HIF-2a and PHD3; actin was
used as a loading control. B) Breast and prostate cancer cell lines were transfected with an HRE-luciferase reporter vector and Renilla luciferase vector
and then subjected to hypoxia (1% O2) or normoxia for 24 hours. Luciferase activities after 24 hours of hypoxia were determined and are depicted
relative to luciferase activities in cells under normoxia. Error bars = SEM. n=3 for MCF7 and PC-3. n=2 for MB-435 and DU 145.
doi:10.1371/journal.pone.0014617.g005
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Perturbations in the cellular responses to hypoxia are well known
to play a role in the malignant process. Familial mutations in VHL,a
negative regulator of the HIF-a proteins, results in vascular tumors
of the brain, spinal cord and retina, as well as appearance of renal
clear-cell carcinomas [23]. PHD proteins play a role upstream of
VHL regulation; they hydroxylate HIF-a proteins, creating a
binding site for VHL [24,25,26]. Thus, it is feasible that
deregulation of PHD activity or expression could also contribute
to the malignant process. In fact, an absence of PHD3 upregulation
following hypoxia has been observed in multiple human cell lines
from tumors of the breast, prostate and brain [10,16]. A recent
clinical study of breast tumors containing BRCA mutations supports
the hypothesis that PHD3 plays an important role in malignancy.
This study found a positive correlation between decreased PHD3
expression and a basal phenotype, which is considered a higher
grade and more aggressive tumor [27].
Figure 6. PHD3 mRNA expression is downregulated in multiple primary human prostate cancer specimens. A) Total mRNA was
isolated from frozen sections of primary human prostate cancer specimens with Gleason scores ranging from 7–9. Quantitative real-time PCR was
performed using PHD3 specific TaqMan primer-probe. Relative PHD3 mRNA expression for each tumor sample is represented as (average dCt of n=3
benign prostate tissue samples) – (dCt tumor sample). Samples were normalized to GAPDH. Dotted lines represent +/2 1 SD for benign tissue PHD3
mRNA expression. B) Box plot depicting PHD3 mRNA expression from samples shown in A. p value is based on ANOVA between 3 benign samples
and 10 malignant samples.
doi:10.1371/journal.pone.0014617.g006
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PHD3 in breast, prostate, melanoma and renal cell carcinoma cell
lines, and the absence of PHD3 mRNA induction upon hypoxic
stimulus. PHD3 expression could be recapitulated in some PHD3
negative cell lines after treatment with 5-Aza-dC, a DNA
methyltransferase inhibitor, implicating DNA methylation as a
mechanism for the decreased expression of PHD3 mRNA in these
cell lines. PHD3 promoter methylation was verified by sequence
analysis of PCR products cloned from bisulfite-treated genomic
DNA. We found that among the human cancer cell lines
investigated, PC-3, MB-435, HS578T, and 769-P cell lines have
hypermethylated PHD3 CpG islands. Furthermore, the PHD3
promoter region was more resistant to DNase I in PC-3 cells
(hypermethylated PHD3 promoter) compared to MCF7 cells
(hypomethylated PHD3 promoter). The methylation of the PHD3
promoter in these carcinoma cell lines appears to be aberrant since
insignificant DNA methylation was found in the non-transformed
cell counterparts of prostate and mammary epithelial cell lines
NPrEC and HME1 respectively. The apparently aberrant PHD3
promoter methylation status in these cell lines is the likely
mechanism, at least in part, for PHD3 transcriptional suppression
because DNA methylation is typically associated with a condensed
heterochromatin state, and is known to inhibit transcription factor
binding to promoter regions of genes [28].
Although all members of the PHD family have the ability to
hydroxylate both HIF-1 and HIF-2a, the specificities appear to
differ slightly. PHD2 has been reported to play a more
pronounced role in the regulation of HIF-1a, whereas PHD3
more strongly affects HIF-2a stability [10]. Therefore, it would
seem likely that loss of PHD3 expression by promoter methylation
would convey a cellular advantage mediated through increased
HIF-1a and/or HIF-2a stability during hypoxia. This could lead
to increased expression of VEGF and erythropoietin with
subsequent vascular recruitment. Tumors of the breast, skin,
kidney and prostate, being solid tumors, would certainly benefit
from an increase in vascular supply to hypoxic areas. In fact, there
is evidence that cell lines from other solid tumors downregulate
PHD3 as well. Henze et al. have shown that several glioma cell
lines display little to no PHD3 protein expression during
normoxia, with no induction upon hypoxia when compared to
other glioma cell lines studied [16]. Our results would predict that
a subset of those cell lines have aberrant methylation of the PHD3
CpG island. Interestingly, HIF-2a protein levels after 18 hours of
hypoxia appeared lower in PHD3 non-expressing cells than those
in cells expressing relatively high levels of PHD3 [16]. This is the
opposite of what we had expected, and may demonstrate the
ability of other PHD family members to substitute for the loss of
PHD3 expression in regulating HIF-1a and HIF-2a stability. This
hypothesis is supported by data from Appelhoff et al., who
measured relative protein amounts of PHD isoforms in multiple
cell lines. In cell MB-435 and ZR751 cell lines where PHD3 is low
or absent, PHD2 protein is greatly elevated.[29]. Similarly, we
found that MCF7 cells, which basally express PHD3 at the mRNA
and protein level during normoxic conditions, also express
relatively high levels of HIF-2a. Taken together, we interpret
these findings to suggest that PHD3 silencing by CpG methylation
may not have a significant impact on HIF-1 and HIF-2a protein
levels in the cell lines that we tested.
In fact, the results of our study support a mechanism whereby
PHD3 silencing by PHD3 CpG island methylation affects
pathways outside of the conventional hypoxic response pathway.
When HIF transcriptional activity was measured through a
hypoxia responsive HRE-luciferase reporter, we observed nearly
equal transcriptional responses to hypoxia in 3 out of 4 cell lines,
which included both PHD3 silenced as well as PHD3 expressing
cell lines. In MCF7 cells, which express PHD3 at the protein level
and do not contain PHD3 promoter methylation, we observed
nearly a 15-fold increase in luciferase induction upon hypoxic
treatment. These results suggest that PHD3 expression status does
not significantly affect HIF protein stabilization or HIF transcrip-
tional activity through an HRE containing promoter upon
exposure to 1% oxygen. Therefore, modulation of an alternative
cellular pathway(s) remains an open candidate for mediating the
effects of PHD3 loss in malignancies.
Besides the HIF family proteins, other interacting partners of
PHD3 have already been discovered. PHD3 is a known player in
both neuronal apoptosis and in myoblast differentiation [30,31]
PHD3 also appears to interact with Bcl-2 to induce apoptosis in
H9c2 cells in response to doxyrubicin [32].Furthermore, PHD3
has also been reported to destabilize ATF-4 through a novel
oxygen-dependant domain on ATF-4 [33]. ATF-4 is involved in
the regulation of angiogenesis and metabolism [34]. Thus,
upregulation of ATF-4 by a loss of PHD3 could promote cell
survival. In addition, PHD3 has also been recently reported to
inhibit IKKb. An increase in IKKb activity in the absence of
PHD3 could confer a growth advantage to cells through an
increase NFkB signaling [35]. Constitutive NFkB activity is an
important and common event in T- and B-cell derived
malignancies [36,37] and may explain the PHD3 promoter
methylation recently reported in plasma and B-cell neoplasia by
Hatzimichael et al. [17]. These interesting prospects related to
identification of the downstream targets of PHD3 signaling will
undoubtedly become a focus of future investigations.
Our inability to detect PHD3 promoter DNA methylation in
primary human prostate tumors was surprising, however our
results are supported by a recent study by Huang et al. [38], who
screened 168 invasive breast carcinomas and did not find evidence
of PHD3 DNA methylation using melting curve analysis of bisulfite
converted DNA. We cannot rule out the possibility that a low level
of semi-methylated PHD3 CpG islands are present in their samples
as the ‘‘intermediately methylated’’ controls were not truly
intermediately methylated, but rather were mixtures of 100%
methylated DNA with 0% methylated DNA. Nonetheless, it seems
clear that a large proportion of primary epithelial tumors does not
contain a high degree of PHD3 promoter methylation, and may
not be the ideal specimens for detection of methylation at this
locus. Given PHD39s purported ability to negatively regulate the
NFkB pathway [30,35], and the widely reported involvement of
NFkB in cell migration and metastasis [39,40], future studies on
PHD3 CpG island methylation in clinical samples of metastatic
disease as opposed to primary tumors may yield more positive
results.
Here, we are the first to report DNA methylation of the PHD3
CpG island in solid tumor cell lines derived from diverse cell types.
PHD3 methylation in carcinoma cells was associated with their
inability to appropriately upregulate PHD3 mRNA upon exposure
to hypoxia. We are also the first to show evidence that this
aberrant expression fails to correlate with an increase in HIF
protein accumulation and transcriptional activity upon exposure
to hypoxia in the cell lines examined. The presence of PHD3
promoter hypermethylation and PHD3 silencing in such a wide
range of cancer types suggests this might be a common event that
elicits a selective advantage for tumors. Our data suggest that at
least in some cell lines, the nature of this advantage may extend
beyond hypoxia resistance. Furthermore, the selective event may
occur during or after the process of invasion/metastasis, as we and
others have not found evidence of methylation in primary solid
tumors [38].
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Figure S1 Validation of methylated DNA enrichment as a tool
for detecting methylated CpG regions in human genomic DNA.
A) Genomic DNA from human melanoma and breast cancer lines
was enriched for methylated CpG dinucleotides at the PHD3 CpG
island using the MethylMiner kit, followed by quantitative real-
time PCR analysis using PHD3 CpG island-specific PCR primers.
S = supernatant, representing unmethylated DNA. E1 - E5
represents elutions with 200, 650, 1100, 1550, 2000 mM NaCl
respectively. Input = 1/60th total input DNA. Total amounts of
eluted DNA from each fraction are represented as a fraction of
input (left). Methylated CpG sequences from bisulfite-converted
DNA in the corresponding cell lines are depicted for comparison
(right). B) Control 100% methylated and 0% methylated oligos
supplied by the MethylMiner kit were subjected to the
MethylMiner protocol. S = supernatant, representing unmethy-
lated DNA. E1-E5 represent elutions with 200, 650, 1100, 1550,
2000 mM NaCl respectively. Identical volumes of DNA from each
eluate were subjected to quantitative real-time PCR using primers
supplied by the MethylMiner kit. DNA content in each fraction is
represented as arbitrary units.
Found at: doi:10.1371/journal.pone.0014617.s001 (10.36 MB
TIF)
Figure S2 The methylated PHD3 gene in non-expressing cells is
maintained in a less accessible state than the non-methylated
PHD3 gene in expressing cells. A) Nuclei from PHD3-positive
MCF7 and PHD3-negative PC-3 carcinoma cell lines were
isolated and enzymatically restricted with DNase I. Primers CA1
and CA2 (see Fig. 3A) were used for quantitative real-time PCR
(right panels) to amplify a region also assessed for cytosine
methylation. Accessibility indices (left panels) were calculated as
follows: AI = 2((Ct DNase treated) - (Ct Untreated)). B) GAPDH
accessibility indices were simultaneously assessed as a control for a
constitutively expressed gene in both cell lines.
Found at: doi:10.1371/journal.pone.0014617.s002 (3.00 MB TIF)
Figure S3 PHD3 antibody specificity. PC3 cells were transduced
with an increasing MOI of adenoviral-PHD3 vector. Western blot
using Novus100–139 antibody co-incubated with anti-actin
antibody indicated an approximately 27 kDa band in MCF7 cells
that migrates at the same molecular weight as a band present in
PHD3 transduced PC3 cells.
Found at: doi:10.1371/journal.pone.0014617.s003 (3.00 MB
TIF)
Figure S4 Methylated DNA enrichment of genomic DNA
isolated from primary human prostate cancer. A) Total genomic
DNA was isolated from frozen sections of 7 malignant prostate
cancers and 3 benign prostate samples and subjected to the
MethylMiner protocol. Tumor sample number corresponds to
samples shown in figure 6A. S = supernatant, representing
unmethylated DNA. E1-E4 represents elutions with 300, 550, 800,
and 2000 mM NaCl. PHD3 CpG island DNA content in each
fraction is represented as a fraction of total PHD3 CpG island
DNA present in input.
Found at: doi:10.1371/journal.pone.0014617.s004 (8.41 MB
TIF)
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